Inorganic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myelogenous Leukaemia

Youssef Ghosn, MD1, Mohammed Hussein Kamareddine, MD1, Antonios Tawk, MD1, Carlos Elia, PhD2, Ahmad El Mahmoud, MD1, Khodor Terro, MD1, Nadia El Harake, MD1, Bachar El-Baba, MD1, Joseph Makdessi, MD3, and Said Farhat, MD4

Abstract
Chronic myeloid leukemia is a myeloproliferative disease where cells of myeloid lineage display a t(9;22) chromosomal translocation leading to the formation of the BCR/ABL fusion gene and the continuous activation of tyrosine kinases. This malignancy has a peak incidence at 45 to 85 years, accounting for 15% of all leukemias in adults. Controlling the activity of tyrosine kinase became the main strategy in chronic myeloid leukemia treatment, with imatinib being placed at the forefront of current treatment protocols. New approaches in future anticancer therapy are emerging with nanomedicine being gradually implemented. Setting through a thorough survey of published literature, this review discusses the use of inorganic nanoparticles in chronic myeloid leukemia therapy. After an introduction on the basics of chronic myeloid leukemia, a description of the current treatment modalities of chronic myeloid leukemia and drug-resistance mechanisms is presented. This is followed by a general view on the applications of nanostrategies in medicine and then a detailed breakdown of inorganic nanocarriers and their uses in chronic myeloid leukemia treatment.

Keywords
myeloid, leukemia, inorganic, nanoparticles, drug resistance

Abbreviations
Ap-SWNTs, antibody oxidized single-walled carbon nanotubes; BrTet, 5-bromotetrandrine; CCyR, complete cytogenic response; CDK, cyclin-dependent kinase; CLSM, confocal laser scanning microscopy; CML, chronic myeloid leukemia; CMR, complete molecular response; CNTs, carbon nanotubes; CTAB, cetyltrimethylammonium bromide; DNA, deoxyribonucleic acid; DNR, daunomycin; ER, endoplasmic reticulum; f-SWNTs, ammonium functionalized carbon nanotubes; FACS, fluorescence-activated cell sorting; FDA, Food and Drug Administration; HSA-SWNTs, human serum albumin single-walled carbon nanotubes; MDR, multidrug resistance; MNPs, magnetic nanoparticles; mRNA, messenger RNA; NIR, near infrared radiation; NPs, nanoparticles; o-SWNTs, oxidized single-walled carbon nanotubes; P-gp, permeability glycoprotein; Ph, Philadelphia chromosome; RNA, ribonucleic acid; RNAi, RNA interference; ROS, reactive oxygen species; siRNA, small interfering ribonucleic acid; SWNTs, single-walled carbon nanotubes; TKIs, tyrosine kinase inhibitors; TNF, tumor necrosis factor; UV, ultraviolet.

Received: January 09, 2019; Revised: March 25, 2019; Accepted: April 24, 2019.

1 Faculty of Medicine and Medical Sciences, University of Balamand, El-Koura, Lebanon
2 Faculty of Engineering, Chemical Engineering, University of Balamand, El-Koura, Lebanon
3 Department of Hematology – Oncology, Saint George Hospital University Medical Center, Beirut, Lebanon
4 Department of Gastroenterology, Saint George Hospital University Medical Center, Achrafieh-Beirut, Lebanon

Corresponding Author:
Said Farhat, MD, Department of Gastroenterology, Saint George Hospital University Medical Center, Anis Kfoury, Achrafieh, Beirut 1100, Lebanon.
Email: saidfarhat@hotmail.com
Introduction and Clinical Features

Chronic myeloid leukaemia (CML) is a hematopoietic malignancy characterized by neoplastic proliferation of mature myeloid cells, especially granulocytes and their precursors. Chronic myeloid leukaemia results from genetic abnormalities marked by the presence of the Philadelphia chromosome (Ph), which is the product of a reciprocal translocation of Ab1 gene (chromosome 9, long arm) to BCR (chromosome 22, long arm), that is, t(9;22)(q34;q11.2). This fusion results in a constitutive tyrosine kinase activity that leads to the phosphorylation and activation of various downstream proteins promoting cellular proliferation while inhibiting apoptosis.

Chronic myeloid leukaemia accounts for 15% of leukemias in adults with an incidence of 1/100 000,4 and a median age of diagnosis of 60 to 65 years.5 Bone marrow transplantation and chemotherapeutics such as tyrosine kinase inhibitors (TKIs) are the prevalent approaches for CML treatment.6 Cure from CML is unattainable via TKI monotherapy as it remains a clinical challenge especially in the advanced cases. The only potential curative approach is allogeneic bone marrow transplantation. This statement remains true especially with CML cells developing multidrug resistance (MDR) properties, thus decreasing the efficacy of certain TKIs such as imatinib.6 The potential development of cancer and drug resistance are the main disadvantages of chemotherapy.7 As per the literature, the cytogenetic response achieved with TKI monotherapy is seen in only 12% of the cases, whereas the hematological response achieved with TKI monotherapy is seen in 50% of the cases. Moreover, the median range of survival ranges between 6 months and 11.8 months.8,9 New research indicates that means to overcome such disadvantages and lack of complete cure from CML lies in the combination of new innovative agents with current treatments. Nanotechnology has shown significant potential as a new approach in the treatment of CML.10

Nanoparticles (NPs) are considered as 2- or 3-dimensional particles measuring anywhere between 1 and 100 nm.11,12 Their usefulness has seen their popularity surge in recent times to be utilized in a wide variety of fields. They have begun to be applied in the management of malignancies13,14 and have been found to be useful in medical imaging. Recent discoveries show the use of NPs as antimicrobial agents and more importantly as targeted drug delivery systems.11,15 Nanoparticles exhibit revolutionary advantages in the medical field. However, more studies should be conducted to assess for potential toxicity on the human body and adverse effects on the environment. For example, some studies showed that certain NPs such as ZnO NPs may lead to oxidative stress and DNA damage.16,17

This review aims to compile and discuss current advances in nanomedicine in which NPs are used as a drug-delivery system in the treatment of CML. Both the chemical properties and the clinical applications of NPs are detailed in this study.

Basics of Chronic Myeloid Leukemia

Molecular Changes

Chronic myeloid leukaemia is a myeloproliferative malignancy affecting hematopoietic stem cells and is caused by a hyperactive tyrosine kinase activating antiapoptotic and cellular proliferation proteins (such as ERKs and PKB/pAkt) via phosphorylation. Some of the antiapoptotic effects are due to inhibition of the p38 and JNK pathways as well as mutations in p53 and Apaf-1 and an induced deficit in FASR.18-20 The cellular proliferation proteins activate pathways involving RAS, MEK, Erk, Stat5, and PI3K/AKT.21 The constitutive tyrosine kinase activity is most commonly due to a 9;22 chromosome reciprocal transformation leading to the fusion of BCR and ABL (BCR/ABL fusion gene); the product of which is the p210bcR-abl fusion protein.19

Clinical Features

As much as 50% of patients with CML are asymptomatic and are diagnosed incidentally after routine check-ups.22 Even in symptomatic cases, symptoms are not always specific. Around 50% to 75% of patients complain of left upper quadrant pain owing to splenomegaly. Patients may also experience early satiety, display symptoms of anemia, and night sweats. Other symptoms may include bleeding (due to platelet dysfunction) and thrombocytosis.22,23 A minority of patients (5%) may present with hyperviscosity symptoms due to the high degree of leukocytosis.1

Chronic myeloid leukaemia progression can be broken down into 3 different stages depending on the following factors: chronic (the most common at presentation), accelerated, and blast.24

Conventional Methods in CML Treatment: Advantages and Drawbacks

As hematological malignancies are not treatable by radiotherapy or surgery, chemotherapy is the main approach in the management of leukemias. In patients with CML, treatment depends on many factors including phase of the disease and availability of stem cell donor.

Tyrosine kinase inhibitors such as Imatinib (Gleevec), Dasatinib (Sprycel), and Nilotinib (Tasigna) are considered the standard of CML treatment. Drug dosage increase can be considered throughout treatment; however, higher doses impose greater toxicity. Generally, the treatment starts with Imatinib and it can be replaced by other TKIs. Ponatinib, for example, is used in cases of T315I mutation development in the leukemic cells.25,26 If these drugs fail or ponatanib appears not to be tolerated, a trial of chemotherapy or interferon can be initiated. Omacetaxine has been used with varying degrees of success in T315I mutation cases nonresponsive to standard therapy. Finally, stem cell transplantation is especially helpful for patients who have been successful in finding a suitable donor and remains the only treatment to cure CML.27,28
Within 1 year of chronic-phase CML treatment with imatinib, up to 70% of patients showed complete cytogenetic response (CCyR) and even higher response rate with the newer TKIs. Moreover, complete molecular response (CMR) was observed after a year in many patients. Current recommendations are to continue TKI therapy indefinitely due to the ability of the BCR-ABL translocation and CML cells to recur, as seen in half of the treated patients. Unfortunately, the prognosis of CML is worse in both the accelerated phase and the blast phase of the disease with fewer successful pharmaceutical treatments and transplants.37,38

As previously stated, Imatinib (on account of its superior anti-leukemic effects) is currently mainstay therapy used in CML treatment.29 However, Imatinib resistance has been described and has been associated with BCR/ABL mutations in most cases.30,31 Resistance has also been associated with BCR/ABL amplification, high drug efflux from leukemic cells, BCR/ABL mRNA overexpression, T315I mutation, or other cytogenetic abnormalities.31,32 Furthermore, leukemic stem cells in CML are imatinib-resistant by the way of quiescence and/or higher expression of drug-efflux-related proteins. Therefore, a major problem of TKIs is the development of drug tolerance which is observed in roughly 30% of patients.32 Although TKIs are the most successful pharmaceutical treatment for CML, complete cure from CML cannot be achieved without allogeneic transplantation.5 Drug resistance and cancer relapse are major disadvantages being faced with current treatments.7 Therefore, employing new agents in combination with existing treatments is of critical importance to improve cancer cells’ response to drugs, to prevent later relapse, and to successfully cure CML without the need for transplantation. The need to overcome current drug drawbacks has pushed researchers to develop new treatment strategies with nanotechnology emerging as a possible new approach in the management of CML.10

Multidrug Resistance

One of the major reasons of the failure of chemotherapy and cancer relapse in hematological malignancies is MDR in which cancerous cells develop resistance against the cytotoxic effects of chemotherapeutic drugs via various complex mechanisms of action. Despite drug resistance being initiated by a certain type of drugs, drug resistance is not drug specific.53 The MDR is attained through mechanisms of downregulation of the production of apoptosis-related proteins such as Bax, caspase-3, and Bcl-2,34 drug excretion, recovery from drug-induced DNA damage, and changes in the activity of enzymes functioning in drug metabolism.35 Nevertheless, the most important mechanism of MDR is drug excretion via permeability glycoprotein (P-gp),36 which is a transmembrane efflux pump, encoded by Mdr1 gene functioning to decrease intracellular drug concentrations by actively transporting the drug outside the cells.37,38 The overexpression of Mdr1 gene leads to excessive production of P-gp, increasing cell resistance to chemotherapeutic drugs; thus, increasing the chance of cancer recurrence and worsening the prognosis.39 The overexpression of P-gp was initially found in tumor stem cells and residual cells remaining after chemotherapy administration.40-42 Understanding the mechanism of P-gp induced MDR has pushed researchers to develop P-gp inhibitors providing a strategy that can improve the treatment of myelodysplastic syndrome with P-gp mediated MDR.4 In addition, alteration in the expression of Bcl2 is also associated with MDR and tumor development.34 Many chemotherapeutic drugs target intrinsic mitochondrial apoptosis pathway, also known as cytochrome c/Apaf-1/caspase-9 pathway. Excessive activation of Bcl2 in cancerous cells causes arrest in the mitochondrial pathway by inhibiting Bax, which eventually prevents activation of Caspase 3 essential for the final steps of apoptosis.43,44 It has been proven that, in hematologic malignancies, there is an increase in Bcl2 and Bax expression to up to 21%.45

As previously mentioned, in certain CML patients undergoing treatment with TKIs, the cancer cells develop resistance against TKIs via T315I mutation. Moreover, Ponatinib, the only effective TKI drug against this mutation, is the treatment of choice in such patients despite its many side effects.

With an ever-increasing rate of resistance to treatment, new therapeutic targeting methods must be developed. Nanomedicine emerges as a promising therapeutic approach of targeted drug delivery to overcome drug resistance.

Nanomedicine in CML Treatment

Targeted drug delivery provides an efficient approach for the specific delivery of the chemotherapeutic drug(s) to cancer cells sparing normal cells from their cytotoxic effect.46,47 While designing a drug delivery system, several measurements must be taken into consideration to ensure success. The drug delivery system must ensure an efficient delivery of the drug to the targeted cells while preserving the drug’s molecular bioactivity. Moreover, the kinetics of the drug loading and drug release should be controlled to achieve a desirable and adequate loading and release of the drug.48,49 Nanoparticles present several advantages when used as drug delivery systems. For example, drug delivery via NPs improves the water solubility of the drug in cancer cells. Moreover, drug delivery by NPs enhances the intracellular uptake of the drug and aids in preserving its metabolic stability. The circulation time of the drug is also enhanced. The NPs allow targeted drug delivery (by both passive and active strategies), thus sparing the cytotoxic effect of the drug to the normal cells.50,51 In short, when loaded into nanocarriers, chemotherapeutic drugs can escape degradation while displaying lower toxicity, superior efficacy, and solubility.52,53

However, using NPs requires a deep understanding of various parameters that determine their function inside a living entity such as a cell or the entire human body. The toxicity, uptake, and half-life of NPs depends on both intrinsic factors such as surface charge, particle size, and shape like zeta potential, and surface area and extrinsic factors such as the activity of the reticuloendothelial system and renal clearance.54,55 For example, the shape and size of NPs were shown to affect their
cytotoxicity as well as optical, catalytic, and electromagnetic characteristics.\textsuperscript{1} The NPs with less than three facets such as spherical NPs are less reactive than truncated triangular nano-plates.\textsuperscript{56} On the other hand, the half-life of NPs is highly dependent on their interaction with the reticuloendothelial system, especially macrophages.\textsuperscript{57} The ability of the reticuloendothelial system to clear NPs depends on the absorption of opsonins by NPs, activating macrophages that are the main leukocytes responsible for NP elimination. Reducing NP clearance by macrophages can be achieved by coating NPs with a hydrophilic layer, using polymers such as polyethylene glycol through a process called PEGylation.\textsuperscript{58,59} Other advantages of PEGylated NPs are the low toxicity demonstrated in both in vivo and in vitro studies\textsuperscript{58,59} and the ability to decrease renal drug clearance.\textsuperscript{60,61} Finally, when NPs reach the targeted tissues, endocytosis is the main mechanism by which these hydrophilic NPs are transported into cells. This active transport mechanism consists of engulfing molecules in incised cytoplasmic membrane-derived vesicles, thus absorbing these molecules into the interior of cells.\textsuperscript{62}

**Classification of Inorganic NPs**

According to RSC Advances by Aula et al\textsuperscript{(2015)},\textsuperscript{63} NPs can be divided into organic and inorganic. In this review, inorganic NPs will be discussed and categorized as follows:

- Carbon nanotubes (CNTs)
- Noble metal NPs
- Silver-based NPs
- Gold-based NPs
- Magnetic NPs (Fe$_3$O$_4$ NPs)
- ZnO NPs
- Copper oxide NPs (CuO NPs)

In contrast to the inorganic NPs, lipid nanocapsules and polymer NPs are widely studied, and have outstanding advantages in biocompatibility, but possess major drawbacks such as instability and a low-loading capacity. So far, only 6 types of inorganic NPs including ZnO,\textsuperscript{64} copper, gold,\textsuperscript{65} silver and Fe$_3$O$_4$ NPs,\textsuperscript{62} and CNTs have been studied as possible drug delivery systems for CML.

**Inorganic NPs for CML Treatment**

**Carbon Nanotubes (CNTs)**

Carbon nanotubes are hollow tubes formed by rolling carbon polymer sheets that can cross cellular membrane without generally inflicting cellular injury.\textsuperscript{66,67} Although CNTs are generally considered nontoxic and biocompatible,\textsuperscript{66,68} using CNTs without surface modification could be cytotoxic to cells and it has been shown that residual heavy metals in CNTs induce cellular cytotoxicity.\textsuperscript{12,69} The CNT toxicity remains the most concern for their use in the clinical setting. However, studies appearing in the literature related to the toxicology of CNTs presented confusing results. Some studies claimed that CNTs are responsible for both acute and chronic toxicity while some studies showed insignificant toxicity, should reaction condition be optimal.\textsuperscript{70} Functionalized CNTs with no residual heavy metals, especially single-walled carbon nanotubes (SWNTs), are considered safe at the cellular level with remarkable biocompatibility.\textsuperscript{71,72} The biocompatibility of functionalized SWNTs, their ability to be used as vectors, and the ease of CNT endocytosis make them useful as delivery vehicles for various biomolecules including RNA,\textsuperscript{73,74} proteins,\textsuperscript{67,75} DNA,\textsuperscript{75,76} and siRNA. Additionally, RNA and DNA could be adsorbed as double or single strands while binding noncovalently to SWNT surfaces.\textsuperscript{77} An important characteristic of CNTs is that drugs such as doxorubicin could be carried by CNTs through physical adsorption without being covalently bound, thus avoiding chemical interactions between CNTs and the drug.\textsuperscript{78} SNX-2112 is a promising chemotherapeutic agent with potential use in various types of cancer since it is a Hsp90 inhibitor. However, SNX-2112 is both hydrophobic and lipopholic, which limits its use in clinical settings. Zheng et al\textsuperscript{(2016)} added chitosan (CHI) noncovalently to SWNTs to increase their biocompatibility. The CHI-SWNTs were then used as delivery system for SNX-2112 delivery to the K562 cells. The results showed significant inhibition of the K562 cells and the abundant expression of apoptosis-related proteins.\textsuperscript{79} Since CNTs could absorb near-infrared radiations (NIR) and laser effectively, exposing CNTs based nanocarriers to NIR at the level of the targeted cells improves drug release.\textsuperscript{80,81} The large aspect ratio of CNTs compared to other drug delivery systems, allows CNTs to have more carrying capacity and more efficient transfer across phospholipid cellular membranes. This was demonstrated by comparing the transfer of siRNA using CNTs to that using liposomes.\textsuperscript{82,83} Moreover, the condensation of nucleic acids and their delivery across the cellular membrane and into mammalian cells was achieved and showed to be effective using CNTs bound to ammonium as the functional group.\textsuperscript{84,85} Li et al\textsuperscript{(2010)} used P-glycoprotein antibody functionalized CNTs in an attempt to overcome MDR CML.\textsuperscript{86} This study investigated the specificity and cytotoxicity of P-gp antibody oxidized single-walled carbon nanotubes (Ap-SWNTs) loaded with Dox to MDR K562R CML cells. First, the experiment showed 458 times higher expression of P-gp in K562R compared to K562 sensitive (K562S) cells. The overexpression of P-gp on leukemic cellular membranes was considered to infer the specificity of the antibody Ap-SWNTs to MDR cells. This was showed by the increased binding affinity of Ap-SWNTs to K562R where the affinity of Ap-SWNTs to K562R was 23-folds higher than with K562S. Additionally, by physical adsorption, Dox was loaded on the Ap-SWNTs. This makes it possible to release the drug at the level of targeted cells using near infrared radiation (NIR) thus increasing drug specificity and drug release capacity while preserving molecular integrity by minimizing reaction between doxorubicin and CNTs. The high surface to volume ratio of SWNTs and the peripheral oxidation of the CNTs increase Dox loading capacity thus better cytotoxic effect even after antibody coupling. The increase
in DOX delivery via Ap-SWNTs into K562R cells compared to free Dox, Dox/human serum albumin-SWNTs, was confirmed using confocal laser scanning microscopy (CLSM). Regarding cytotoxicity, Dox/Ap-SWNTs composite demonstrates the superior cytotoxicity compared to Dox with o-SWNTs (oxidized SWNTs), Ap-SWNTs, HSA-SWNTs, free Dox and Dox/anti-Pgp, with free Dox and Dox/anti-Pgp showing minimal cytotoxicity, where the K562R cell showed increased survival and proliferation with increased incubation time. This increased cytotoxicity using Dox/Ap-SWNTs could be due to the targeted delivery of Dox and due to difficulty of efflux of Ap-SWNTs outside the MDR cells caused by the relatively large size of nanotubes compared to DOX and the stereo-hindrance of the P-gp produced by the A-SWNTs reducing DOX efflux. Wu et al (2014) showed similar results regarding the efficacy and versatility of CNTs for the delivery of chemotherapeutic agents to malignant cells. They first optimized the length of the CNTs by ultrasonication and oxidative acid treatment. Verapamil and Dox were then co-loaded into the CNTs for their delivery into MDR CML cells K562/A02 in which verapamil was the reversal agent for real-time inhibition of P-gp. Their results showed that there was enhanced uptake of DOX, apoptosis induction, and increased sensitivity to the drug.

Yet another approach by Wang et al (2008) used targeted RNAi of cyclin A2 mediated by functionalized SWNTs to arrest proliferation and induce apoptosis in CML K562 Cells. Here, cells were targeted using ammonium functionalized CNTs (f-SWNTs) vectors carrying siRNA in vitro. The siRNA was used to modulate the genes expression of cancer-related genes such as cyclin A2 and CDK. The siRNA with specificity to cyclin A2 was used to suppress the overexpression of cyclin A2 thus arresting cellular G1–S phase and G2–M transitions by decreasing the levels of formation of cyclin–CDK complex leading to increased intracellular E2F activity and eventually arrest in proliferation and apoptosis. The experiment showed reduced expression of cyclin a2 RNA and protein, with no detectable toxicity induced by the f-SWNTs. The siRNA showed specificity to CML cells that were attributed to an increased sensitivity of rapidly proliferating cells to siRNA compared to normal dividing cells that could be caused by differences in cellular membrane.

Silver Nanoparticles

The applications of silver NPs (AgNPs) are broad and diverse. The antimicrobial properties of AgNPs make them suitable for usage as antiseptics in various manufacturing and consumer products in addition to their usage in the biomedical field. Although the cytotoxicity of AgNPs might limit their use, AgNPs show potential uses in the treatment and management of various diseases including ocular neovascular diseases, MDR tumors, and immunological and inflammatory diseases. In the treatment of cancers, AgNPs show cytotoxic effects against a number of leukemia cell lines including Jurkat cells and THP-1. How AgNPs affects cell cycle and apoptotic pathways varies with AgNPs concentration and the targeted cell types. Possible mechanisms of AgNP cellular uptake include endocytosis, micropinocytosis, or phagocytosis.

Guo et al (2008) investigated the cellular uptake and cytotoxic effects of AgNPs on CML. The uptake of AgNPs was shown to increase in a dose-dependent manner, which was demonstrated using dark field microscopy and further confirmed by AAS analysis. When coated with PVP, inhibitors of endocytosis, their uptake was prevented demonstrating the role of receptor-mediated endocytosis in AgNPs uptake. This study and another more recent study conducted by Guo et al demonstrated that exposure to AgNPs causes the generation of reactive oxygen species (ROS) causing oxidative stress-induced apoptosis and cellular arrest at the S-phase of the cell cycle. The initial addition of AgNPs displayed a dose-dependent increase in ROS, and the number of cells at the S phase of cell cycle. The addition of vitamin C (an antioxidant) to K562 cells subjected to AgNPs reversed cellular cytotoxicity, reduced the apoptosis induced by AgNPs, and increased expression of Cyclin A and CDK2 genes expression, which were initially inhibited by AgNPs.

Cytotoxic effects of AgNPs were also evaluated and shown to induce cell death in a dose-dependent manner as flow cytometry analysis suggested significant cell shrinkage at the respective high AgNPs concentrations by the decrease of forward scatter’s mean intensity of the treated k562 cells compared to untreated cells.

Interestingly, the effect of AgNPs on CML cells isolated from 4 patients was evaluated. AgNPs showed overall suppression of the viability of the isolated CML cells, but the samples showed variable sensitivity to AgNPs treatment in contrast to the normal cells isolated (human bone marrow mononuclear cells and human cord blood mononuclear cells). Compared to normal cells, CML cells isolated from 3 of the patients showed sensitivity to AgNPs at concentrations lower than that of normal cells (from 1.25 to 5 μg/ml), which indicates that some patients are more sensitive to AgNPs treatments than others, and that AgNPs exhibit increased cytotoxicity against CML cells compared to normal cells. The data obtained suggested that AgNPs could provide a novel opportunity for the treatment of CML.

Gold Nanoparticles

Gold NPs (AuNPs; approved by the FDA) are used in various biomedical applications due to their good biocompatibility, small size, low toxicity, easy surface modification, and controlled drug release. Historically, gold-based chemicals were used for various therapeutic purposes and now gold NPs are being explored for application in cancer treatment, where they have demonstrated effectiveness in reducing tumor necrosis factor (TNF)-mediated toxicity in antitumor treatment. They have also showed potential applications in photothermal cancer therapy. The cytotoxicity
of AuNPs is attributed to surface-modified ligands and particle size. That is, larger AuNPs have lower cytotoxicity, and AuNPs conjugated with, for example, PEG, cysteine, citrate, biotin, and glucose, are less toxic to cells than those linked to cationic ligands, such as cetyltrimethylammonium bromide (CTAB).\textsuperscript{12,109} Nanoparticles such as AuNPs are rapidly eliminated by the reticuloendothelial system, particularly macrophages, thus limiting their use in cancer therapy. This limitation could be overcome when AuNPs are PEGylated, which limits the recognition and clearance of NPs by macrophages, prolonging their circulating half-life.\textsuperscript{58,59} Therefore, due to its important functions, PEG has been used to stabilize the AuNP and to facilitate its use in biomedical applications. Huang et al (2014) showed that PEG-AuNPs kill K562 cells in a dose- and time-dependent manner.\textsuperscript{110} The K562 cells treated with PEG-AuNPs were observed under a light and Transmission Electron Microscope (TEM). The cells showed a decrease in size after initiation of PEG-AuNPs treatment, with a number of cells showing apoptotic changes. TEM showed that PEG-AuNPs preferentially accumulated in cytoplasmic vacuoles, disrupted the mitochondria, and had an increased intensity around the nuclear membrane without penetrating the nucleus. Additionally, after 48 and 72 h of treatment, PEG-AuNPs resulted in a decrease in the number of cells in G0/G1 and G2/M phases and an increase in the number of cells in the S phase. Induction of apoptosis was also suggested by the time-dependent increase of the percentage of sub-G1 population after PEG-AuNPs treatment. K562 cells were evaluated by flow cytometry to analyze the number of permeabilized cells stained with the potential-sensitive dye, DiOC6. The mitochondrial transmembrane potential was significantly reduced after 24 to 72 h of treatment. This indicates that PEG-AuNPs may induce mitochondrial dysfunction leading to cellular apoptosis. Moreover, in an attempt to understand the mechanism of AuNP-induced cytotoxicity, Tsai et al (2011) used various omic approaches to identify the phosphorylated proteins and differentially expressed proteins/genes in K562 cells treated with AuNPs.\textsuperscript{111} Systems biology analysis was used to systematically analyze the omic data to identify the cellular mechanisms influenced by AuNPs. Unfolded protein-associated endoplasmic reticulum (ER) stress response was the predominant event as revealed by Systems biology analysis of the proteomic data. In parallel with transcriptomic analysis using mRNA expression, microarrays showed ER stress response in the AuNP-treated cells. The AuNPs were shown to be efficient cellular ER stress inducers using ER stress protein markers’ expression assay. Upon ER stress, a cascade of cellular responses was observed chronologically involving ROS increase, mitochondrial cytochrome C release, and mitochondrial damage. Therefore, this study concluded that induction of unmanageable ER stress is the main mechanism by which AuNPs induces cell death. Gossai et al (2016) showed in vitro and in vivo significant study results regarding the efficacy of AuNPs in the delivery and selective release of dasatinib to the malignant cells where the chemotherapeutic agent was customized to be released when cancer cell-specific mRNA was present in the cell. As a result, the cytotoxic effect of both the NPs and the chemotherapeutic agent is significantly reduced while the drug delivery remains highly specific and efficient.\textsuperscript{112}

### Magnetic Nanoparticles

Low toxicity, minimal impact on metabolism and magnetic properties makes magnetic NPs (MNP) one of the most commonly used materials in various biomedical applications, especially cancer treatment.\textsuperscript{113,114} The MNPs help improve the efficiency of cancer treatment via targeted delivery of anticancer drugs and reversal of drug resistance.\textsuperscript{115,116} To avoid MNPs aggregation in vivo, they can be coated with hydrophobic or hydrophilic polymers. Additionally, MNPs should retain their magnetic properties while being biocompatible, having high drug-loading capacity, aqueous dispersibility, and the desired drug release profile.\textsuperscript{117}

Chen et al (2008) evaluated the MDR reversal activity of Fe3O4 (nano–Fe3O4) and 5-bromotetrandrine (BrTet) on MDR cell line K562/A02 solitarily or in combination; and investigated the mechanism of this reversal.\textsuperscript{118} BrTet is a more potent derivative of tetrandrine (a calcium channel antagonist), which possesses anti-MDR characteristics attributed to its ability to reinforce drug-induced apoptosis by increasing intracellular drug concentration mainly through downregulation of mdr1 mRNA or P-gp.\textsuperscript{119} The proliferation of MDR K562/A02 cells that were cultured with daunomycin (DNR) alone or in combination with nano–Fe3O4, BrTet, or both for 48 h was evaluated by MTT assay. The DNR accumulation and P-gp of MDR K562/A02 were analyzed by fluorospectrophotometry. A comparison of IC50 values showed that combination therapy had a powerful and statistically significant effect on the cell lines as the IC50 value was significantly reduced when culturing K562/A02 with combined therapy. Flow cytometry assay showed that nano–Fe3O4 and BrTet increased the DNR accumulation in K562/A02 cells, especially in the group of synergy of these two agents. The mean fluorescence intensity of intracellular DNR significantly increased when incubated with combination reversal reagents compared to either nano–Fe3O4 or BrTet alone. Fluorospectrophotometry assay showed that P-gp was downregulated when pre-treated with nano–Fe3O4, BrTet alone, and in combination with K562/A02 cells. A study by Cheng et al (2009) using the same NPs to overcome CML cell P-gp-induced MDR also showed a synergistic effect of combination therapy.\textsuperscript{119}

Another approach developed by Singh et al (2011) used long circulating lectin-conjugated paclitaxel-loaded MNPs for the treatment of CML.\textsuperscript{120} Paclitaxel is approved by the FDA for various anti-cancer treatments.\textsuperscript{121} It acts by binding microtubes leading to sustained mitotic arrest\textsuperscript{122} and activates stress signalling pathways like JNK and p38MAPK leading to apoptosis.\textsuperscript{123} This study investigated the efficacy of paclitaxel-loaded MNPs, functionalized with a lectin targeting moiety. The use of lectin moiety helps in delivering appropriate drug
concentration specifically to the target tissues through receptor-mediated endocytosis.

*In vivo* studies showed better bioavailability of drug bound to MNPs, which was concluded to be due to the longer circulation half-life of pac-MNPs and lec-pac-MNPs compared to native 6-coumarin. In k562 cells, mitogenic assay showed that, after 48 h of drug administration, lec-pac-MNPs were up to 10 times more cytotoxic than pac-MNPs and 67 times more cytotoxic than intact pac. Fluorescence-activated cell sorting (FACS) analysis showed that cells treated with lec-pac-MNPs had a higher proportion of cells in G2-M compared to other formulations. Using confocal microscopy FACS analysis, it was shown that apoptosis was best induced the most with Lec-pac-MNPs followed by pac-MNPs and intact pac.

**ZnO Nanoparticles**

Guo *et al* (2008) investigated the synergistic cytotoxic effects of different sized ZnO NPs and daunorubicin against k562/A02 cells under UV irradiation. ZnO NPs are able to absorb a large fraction of the UV zone and generate various ROS such as hydrogen peroxide, hydroxyl radical, and superoxide.

---

| Nanocarrier Type               | Ligand | Target          | Coating                        | Drug/Active Compound          | Suggested Mechanism of Action                                                                 | *In vitro* (Cell Lines) | Reference |
|--------------------------------|--------|-----------------|--------------------------------|--------------------------------|-----------------------------------------------------------------------------------------------|-------------------------|-----------|
| Carbon nanotubes               | –      | –               | P-Glycoprotein antibody         | Doxorubin                      | Inhibition of transcription                                                                     | MDR K562R CML           | 86        |
| Carbon nanotubes               | siRNA  | Cyclin A2       | Ammonium functionalized        | SNX-2112                       | Proliferation arrest and apoptosis induction                                                     | CML K562                | 88        |
| Carbon nanotubes               | –      | Hsp90 inhibition| Chitosan functionalized        | Verapamil and Doxorubicin      | Inhibition of P-gp, increase sensitivity to drug, and induction of apoptosis                   | CML K562                | 79        |
| Carbon nanotubes               | –      | P-gp            | –                              | AgNPs                          | Induction of cytotoxicity in CML cells via ROS generation                                        | CML K562                | 63, 99    |
| Silver nanoparticles (AgNPs)   | –      | –               | Polyethylene glycol            | AuNPs                          | Mitochondrial damage, induction of unmanageable ER stress                                        | K562                    | 110       |
| Gold nanoparticles (AuNPs)     | –      | –               | –                              | AuNPs                          | Mitochondrial damage, induction of unmanageable ER stress                                        | K562                    | 112       |
| AuNPs                          | –      | Cancer-specific mRNA | –                              | Dasatinib                      | Release of the TKI when activated by cancer cell specific mRNA                                   | K562                    | 118       |
| Magnetic nanoparticle: 5-Bromotetrandrine | 5-Bromotetrandrine | Calcium channel | 5-Bromotetrandrine | 5-Bromotetrandrine | Downregulation of mdr1 mRNA or P-gp                                                             | K562/A02                | 118       |
| Magnetic nanoparticles: Fe3O4  | –      | Fe3O4           | Paclitaxel                     | Induction of apoptosis         | Synergistic effect with 5-bromotetrandrine                                                       | K562                    | 120       |
| Magnetic nanoparticles        | Lectin | Paclitaxel      | Daunorubicin                   | Synergistic effect with daunorubicin | Increase in P53 and Bax/Bcl-2 ratio                                                              | K562/A02                | 63        |
| ZnO nanoparticles             | –      | –               | –                              | CuO                            | Increase in P53 and Bax/Bcl-2 ratio                                                              | K562                    | 126       |

Abbreviations: CML, Chronic myeloid leukemia; ER, endoplasmic reticulum; mRNA, messenger RNA; ROS, reactive oxygen species; TKI, tyrosine kinase inhibitors.
Therefore, ZnO NPs were combined with daunorubicin for the treatment and the inhibition of MDR in leukemia K562/A02 cells that possess P-gp overexpression. This combined therapy was effective and efficiently enhanced the suppression of the leukemic cell lines when subjected to UV light. The main hindrance to this technique is the difficulty of its application in the treatment of hematological malignancies.

**CuO Nanoparticles**

Shafagh et al (2015), using MTT assay, showed that CuO NPs selectively kill cancer cells in a dose-dependent (manifested as ROS generation) manner without affecting normal cells. Acridine orange and propidium iodide double staining was used to confirm CuO NPs induced apoptosis. CuO NPs exposure was associated with increase in tumor suppressor gene P53 and in Bax/Bcl-2 ratio indicating possible mitochondria-mediated cell death pathway.

**Conclusion**

Chronic myeloid leukaemia is a neoplastic proliferation of mature myeloid cells resulting from a translocation between Abl gene and BCR gene, leading to abnormal growth of these cells due to constitutively active TK. Tyrosine kinase inhibitors remain at the forefront of CML treatment. However, they do not lead to complete cure due to lingering quiescent stem cells. The development of resistance to imatinib is not uncommon, and functional “anatomic” resistance has also been reported. The use of NPs, as summarized in Table 1, for the vehiculation of anti-CML drugs may present new approaches in future therapy. The results displayed are promising, with certain NPs overcoming MDR, and successful targeting of quiescent stem cells that are common culprits in relapse. Most of these delivery systems demonstrated safety by specifically targeting CML cells and sparing normal cells. However, the majority of NPs were used in experimental settings (in vitro) necessitating further studies and clinical trials in this field. This review dealt with inorganic NPs used in CML therapy, a follow-up review article discussing organic NPs would be a useful addition to the literature regarding NP usage in CML therapy.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Said Farhat, MD https://orcid.org/0000-0002-8071-4681

**References**

1. Grosveld G, Verwoerd T, van Agthoven T, et al. The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. *Mol Cell Biol*. 1986;6(2):607-616.
2. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. *Nat Rev Cancer*. 2005;5(3):172-183.
3. Cortez D, Reuther G, Pendergast AM. The bcr-abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. *Oncogene*. 1997;15(19):2333-2342.
4. Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. *Annals of Hematology*. 2015;94(2):241-247.
5. Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017;28(suppl_4):iv41-iv51.
6. Cotta CV, Bueso-Ramos CE. New insights into the pathobiology and treatment of chronic myelogenous leukaemia. *Ann Diagn Pathol*. 2007;11(1):68-78.
7. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukaemia patients in complete cytogenetic remission following imatinib mesylate treatment. *Blood*. 2003;101(12):4701-4707.
8. Hehlmann R., Saussele S. Treatment of chronic myeloid leukemia in blast crisis. *Haematologica*. 2008;93(12):1765-1769.
9. Bucelli C, Cattaneo D, Ferla V, et al. Ponatinib as a valid alternative strategy in patients with blast crisis-chronic myeloid leukaemia not eligible for allogeneic stem cells transplantation and/or conventional chemotherapy: report of a case. *Case Rep Hematol*. 2017;2017:6167345.
10. Subbiah R, Veerapanidand M, Yun KS. Nanoparticles: functionalization and multifunctional applications in biomedical sciences. *Curr Med Chem*. 2010;17(36):4559-4577.
11. Sakamoto JH, van de Ven AL, Godin B, et al. Enabling individualized therapy through nanotechnology. *Pharmacol Res*. 2010;62(2):57-89.
12. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. *Small*. 2008;4(1):26-49.
13. Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. *Angew Chem Int Ed Engl*. 2010;49(19):3280-3294.
14. Wahab R, Yang Y, Umar A, et al. Platinum quantum dots and their cytotoxic effect towards myoblast cancer cells (C 2C 12). *J Biomed Nanotechnol*. 2012;8(3):424-431.
15. AshaRani PV, Mun GLK, Hande MP, Valiyaveettil S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. *ACS Nano*. 2009;3(2):279-290.
16. Kiessling F, Liu Z, Gärtjens J. Advanced nanomaterials in multimodal imaging: design, functionalization, and biomedical applications. *J Nanomater*. 2010;2010:1-15.
17. Yang H, Liu C, Yang D, Zhang H, Xi Z. Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: the role of particle size, shape and composition. *J Appl Toxicol*. 2009;29(1):69-78.
18. Jacquiel A, Herrant M, Legros L, et al. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. *FASEB J*. 2003;17(14):2160-2162.
19. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343-3356.
20. Nagata Y, Todokoro K. Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. Blood. 1999;94(3):853-863.
21. Jia L, Patwari Y, Kelsey SM, Newland AC. TRAIL-induced apoptosis in type I leukemic cells is not enhanced by overexpression of bax. Biochem Biophys Res Commun. 2001;283(5):1037-1045.
22. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164-172.
23. Savage D, Szydlo R, Goldman J. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol. 1997;96(1):111-116.
24. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med. 1990;88(1):1-8.
25. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91(2):252-265.
26. Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015;15(6):323-334.
27. Fentie A, Woldu M, Worku B. Current management approaches of chronic myeloid leukemia. Cancer Sci Ther. 2017;9(8):595-607.
28. Lima L, Bernal-Mizrachi L, Saxe D, et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer. 2011;117(6):1245-1252.
29. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2409-2417.
30. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science. 2001;293(5531):876-880.
31. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16(11):2190-2196.
32. Dumka D, Puré P, Carayol N, et al. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma. 2009;50(12):2017-2029.
33. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-627.
34. Park M, Kang JA, Choi J, et al. Phytosphingosine induces apoptotic cell death via caspase 8 activation and bax translocation in human cancer cells. Clin Cancer Res. 2003;9(2):878-885.
35. Ünlü M, Kfraz Y, Kaci FN, Özcan MA, Baran Y. Multidrug resistance in chronic myeloid leukemia. Turk J Biol. 2014;38(6):806-816.
36. Li X1, Li JP, Yuan HY, et al. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms. Methods Find Exp Clin Pharmacol. 2007;29(9):607-617.
37. Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009;323(5922):1718-1722.
38. Mahon F, Bello F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003;101(6):2368-2373.
39. Falchi L, Kantarjian HM, Wang X, et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013;88(12):1024-1029.
40. Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells. 2006;24(12):2603-2610.
41. Fojo T, Dean M, Bates S. Tumour stem cells and drug resistance. Nature Reviews Cancer. 2005;5:275-284.
42. Valera ET, Scrideli CA, Queiroz RG, Mori BM, Tone LG. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. Sao Paulo Med J. 2004;122(4):166-171.
43. Sasson R, Amsterdam A. Stimulation of apoptosis in human granulosa cells from in vitro fertilization patients and its prevention by dexamethasone: involvement of cell contact and bcl-2 expression. J Clin Endocrinol Metab. 2002;87(7):3441-3451.
44. Belaud-Rotureau MA, Leducq N, Macouillard Poulleterie de Games F, et al. Early transitory rise in intracellular pH leads to Bax conformation change during ceramide-induced apoptosis. Apoptosis. 2000;5(6):551-560.
45. Meijerink JPP, Mensink EJB, Wang K, et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood. 1998;91(8):2991-2997.
46. Vasil JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat. 2005;4(4):363-374.
47. Spragg DD, Alford DR, Greferath R, et al. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci U S A. 1997;94(16):8795-8800.
48. Sharma US, Sharma A. Liposomes in drug delivery: progress and limitations. Int J Pharm. Elsevier B.V. 1997;154(2):123-140.
49. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.
50. Vauthier C, Dubernet C, Chauviere C, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release. 2003;93(2):151-160.
51. Xu P, Van Kirk EA, Zhan Y, Murdoch WJ, Radosz M, Shen Y. Targeted charge-reversal nanoparticles for nuclear drug delivery. Angew Chem Int Ed Engl. 2007;46(26):4999-5002.
52. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26(1):57-64.
53. Hong S, Peer D, Farokhzad OC, Margalit R, Langer R, Karp JM. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
54. Karakoti AS, Hench LL, Seal S. The potential toxicity of nanomaterials—The role of surfaces. JOM. 2006;58(7):77-82.
55. Fischer HC, Chan WC. Nanotoxicity: the growing need for in vivo study. Curr Opin Biotech. 2007;18(6):565-571.
56. Pal S, Tak YK, Song JM. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium escherichia coli. *Appl Environ Microbiol*. 2007;73(6):1712-1720.

57. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. *Int J Pharm*. 2006;307(1):93-102.

58. Niidome T, Niidome Y, Yamagata M, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. *J Control Release*. 2006;114(3):343-347.

59. Kah JCY, Wong KY, Neoh KG, et al. Critical parameters in the pegylation of gold nanoshells for biomedical applications: an in vitro macrophage study. *J Drug Target*. 2009;17(3):181-193.

60. Bailon P, Won C. PEG-modified biopharmaceuticals. *Expert Opin Drug Deliv*. 2009;6(1):1-16.

61. Schmid SL, Conner SD. Regulated portals of entry into the cell. *Nature*. 2003;422(6927):37-44.

62. Chen B, Cheng J, Shen M, et al. Magnetic nanoparticle of Fe3O4 and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells. *Int J Nanomedicine*. 2009;4:65-71.

63. Aula S, Lakkireddy S, Jamil K, Kapley A, Swamy AVN, Lakkireddy HR. Biophysical, biochemical and toxicological significance of biomedical nanoparticles. *RSC Adv*. 2015;5(59):47830-47859.

64. Guo D, Wu C, Jiang H, Li Q, Wang X, Chen B. Synergistic cytotoxic effect of different sized ZnO nanoparticles and daunorubicin against leukemia cancer cells under UV irradiation. *J Photochem Photobiol B*. 2008;93(3):119-126.

65. Song M, Wang X, Li J, Zhang R, Chen B, Fu D. Effect of surface chemistry modification of functional gold nanoparticles on the drug accumulation of cancer cells. *J Biomed Mater Res A*. 2008;86(4):942-946.

66. Shi Kam NW, Jessop TC, Wender PA, Dai H. Nanotube molecular transporters: internalization of carbon nanotube-protein conjugates into mammalian cells. *J Am Chem Soc*. 2004;126(22):6850-6851.

67. Kam NW, Dai H. Carbon nanotubes as intracellular protein transporters: Generality and biological functionality. *J Am Chem Soc*. 2005;127(16):6021-6026.

68. Cui D, Tian F, Coyer SR, et al. Effects of antisense-myeconjugated single-walled carbon nanotubes on HL-60 cells. *J Nanosci Nanotechnol*. 2007;7(4-5):1639-1646.

69. Sargent LM, Shvedova AA, Hubbs AF, et al. Induction of aneuploidy by single-walled carbon nanotubes. *Environ Mol Mutagen*. 2009;50(8):708-717.

70. Augustine S, Singh J, Srivastava M, Sharma M, Das A, Malhotra BD. Recent advances in carbon based nanosystems for cancer theranostics. *Biomater Sci*. 2017;5(5):901-952.

71. Lacerda L, Bianco A, Prato M, Kostarelos K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. *Adv Drug Deliv Rev*. 2006;58(14):1460-1470.

72. Dumortier H, Lacotte S, Pastorin G, et al. Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. *Nano Lett*. 2006;6(7):1522-1528.

73. Zhao C, Peng Y, Song Y, Ren J, Qu X. Self-assembly of single-stranded RNA on carbon nanotube: Polyadenyllic acid to form a duplex structure. *Small*. 2008;4(5):656-661.

74. Liu Z, Winters M, Holodny M, Dai H. siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. *Angew Chem Int Ed Engl*. 2007;46(12):2023-2027.

75. Kam NW, Liu Z, Dai H. Carbon nanotubes as intracellular transporters for proteins and DNA: An investigation of the uptake mechanism and pathway. *Angew Chem Int Ed Engl*. 2006;45(4):577-581.

76. Kam NW, O’Connell M, Wisdom JA, Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. *Proc Natl Acad Sci U S A*. 2005;102(33):11600-11605.

77. Zheng M, Jagota A, Semke E, et al. DNA-assisted dispersion and separation of carbon nanotubes. *Nat Mater*. 2003;2(5):338-342.

78. Dhar S, Liu Z, Thomale J, Dai H, Lippard SJ. Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. *J Am Chem Soc*. 2008;130(24):11467-11476.

79. Zheng L, Wu S, Tan L, Tan H, Yu B. Chitosan-functionalised single-walled carbon nanotube-mediated drug delivery of SNX-2112 in cancer cells. *J Biomater Appl*. 2016;31(3):379-386.

80. Pastorin G, Wu W, Wieckowski S, et al. Double functionalisation of carbon nanotubes for multimodal drug delivery. *Chem Commun (Camb)*. 2006(11):1182-1184.

81. Xu S, Li Y, Zou H, Qiu J, Guo Z, Guo B. Carbon nanotubes as assisted matrix for laser desorption/ionization time-of-flight mass spectrometry. *Anal Chem*. 2003;75(22):6191-6195.

82. Liu Z, Cai W, He L, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. *Nat Nano* 2007;2(1):47-52.

83. Pantarotto D, Singh R, McCarthy D, et al. Functionalized carbon nanotubes for plasmid DNA gene delivery. *Angew Chem Int Ed Engl*. 2004;43(39):5242-5246.

84. Singh R, Pantarotto D, Lacerda L, et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. *Proc Natl Acad Sci U S A*. 2006;103(9):3357-3362.

85. Zhang Z, Yang X, Zhang Y, et al. Delivery of telomerase reverse transcriptase small interfering rna in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. *Clin Cancer Res*. 2006;12(16):4933-4939.

86. Li R, Wu R, Zhao L, Wu M, Yang L, Zou H. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. *ACS Nano*. 2010;4(3):1399-1408.

87. Wu P, Li S, Zhang H. Design real-time reversal of tumor multidrug resistance cleverly with shortened carbon nanotubes. *Drug Des Devel Ther*. 2014;8:2431-2438.

88. Wang X, Ren J, Qu X. Targeted RNA interference of cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous leukemia K562 cells. *ChemMedChem*. 2008;3(6):940-945.

89. Huang Z, Jiang X, Guo D, Gu N. Controllable synthesis and biomedical applications of silver nanomaterials. *J Nanosci Nanotechnol*. 2011;11(11):9395-9408.
90. Marambio-Jones C, Hoek EMV. A review of the antibacterial effects of silver nanomaterials and potential implications for human health and the environment. J Nanopart Res. 2010;12(5):1531-1551.

91. Zuzana M, Alessandra R, Lise F, Maria D. Safety assessment of nanoparticles cytotoxicity and genotoxicity of metal nanoparticles in vitro. J Biomed Nanotechnol. 2011;7(1):20-21.

92. Tran TB, Nguyen PD, Um SH, Son SJ, Min J. Real-time monitoring in vitro cellular cytotoxicity of silica nano tubes using electric cell-substrate impedance sensing (ECIS). J Biomed Nanotechnol. 2013;9(2):286-290.

93. Gurunathan S, Lee K, Kalishwaralak S, Sheikpranbabu S, Vaidyanathan R, Eom SH. Antiangiogenic properties of silver nanoparticles. Biomaterials. 2009;30(31):6341-6350.

94. Liu J, Zhao Y, Guo Q, et al. TAT-modified nanosilver for combating multidrug-resistant cancer. Biomaterials. 2012;33(26):6155-6161.

95. Guo D, Zhao Y, Zhang Y, et al. The cellular uptake and cytotoxicity of silver nanoparticles in human mesenchymal stem cells. Acta Biomater. 2011;7(1):347-354.

96. Guo D, Zhao Y, Zhang Y, et al. The cellular uptake and cytotoxic effect of silver nanoparticles on chronic myeloid leukemia cells. J Biomed Nanotechnol. 2014;10(4):669-678.

97. Frederix F, Friedt J, Choi K, et al. Biosensing based on light absorption of nanoscaled gold and silver particles. Anal Chem. 2003;75(24):6894-6900.

98. Podsiadlo P, Sinani VA, Bahng JH, Kam NWS, Lee J, Kotov NA. Gold nanoparticles enhance the anti-leukemia action of a 6-mercaptopurine chemotherapeutic agent. Langmuir. 2008;24(2):568-574.

99. Shaw III CF. Gold-based therapeutic agents. Chem Rev. 1999;99(9):2589-2600.

100. Tsai CY, Shiu AL, Chen SY, et al. Amelioration of collagen-induced arthritis in rats by Nanogold. Arthritis Rheum. 2007;56(2):544-554.

101. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006;107(3):459-466.

102. Larocque J, Bharali DJ, Mousa SA. Cancer detection and treatment: the role of nanomedicines. Mol Biotechnol. 2009;42(3):358-366.

103. Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med Sci. 2008;23(3):217-228.

104. Allison RR, Mota HC, Bagnato VS, Sibata CH. Biocompatibility and photodynamic therapy—State of the art review. Photodiagnosis Photodyn Ther. 2008;5(1):19-28.

105. Podsiadlo P, Sinani VA, Kam NWS, Lee J, Kotov NA. Gold nanoparticles enhance the anti-leukemia action of a 6-mercaptopurine chemotherapeutic agent. Langmuir. 2008;24(2):568-574.

106. Paciotti GF, Myer L, Weinreich D, et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 2004;11(3):169-183.

107. Huang Y, Jain PK, El-Sayed IH, El-Sayed MA. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med Sci. 2008;23(3):217-228.

108. Allison RR, Mota HC, Bagnato VS, Sibata CH. Biocompatibility and photodynamic therapy—State of the art review. Photodiagnosis Photodyn Ther. 2008;5(1):19-28.

109. Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: Preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev. 2009;38(6):1759-1782.

110. Huang YC, Yang YC, Yang KC, et al. Pegylated gold nanoparticles induce apoptosis in human chronic myeloid leukemia cells. Biomed Res Int. 2014;2014:182353.

111. Tsai Y, Huang Y, Chao Y, et al. Identification of the nanogold particle-induced endoplasmic reticulum stress by omic techniques and systems biology analysis. ACS Nano. 2011;5(12):9354-9369.

112. Gossai NP, Naumann JA, Li NS, et al. Drug conjugated nanoparticles activated by cancer cell specific mRNA. Oncotarget. 2016;7(25):38243-38256.

113. Gindy ME, Prud’homme RK. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv. 2009;6(8):865-878.

114. Pridgen EM, Langer R, Farokhzad OC. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (Lond). 2007;2(5):669-680.

115. Jordan A, Wust P, Scholz R, et al. Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Int J Hyperthermia. 1996;12(6):705-722.

116. Yan S, Zhang D, Gu N, et al. Therapeutic effect of Fe2O3 nanoparticles combined with magnetic fluid hyperthermia on cultured liver cancer cells and xenograft liver cancers. J Nanosci Nanotechnol. 2005;5(8):1185-1192.

117. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26(18):3995-4021.

118. Chen B, Cheng J, Wu Y, et al. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizing daunorubicin and 5-bromotetrandrine in xenograft nude-mice. Int J Nanomedicine. 2009;4:73-78.

119. Chen B, Cheng J, Wu Y, et al. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizing daunorubicin and 5-bromotetrandrine in xenograft nude-mice. Int J Nanomedicine. 2009;4:73-78.

120. Singh A, Dilnawaz F, Sahoo SK. Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. PLoS One. 2011;6(11):e26803.

121. Knijn A, Brisdelli F, Ferretti A, Iorio E, Marcheggiani D, Bozzi A. Metabolic alterations in K562 cells exposed to taxol and tyrphostin AG957: 1 H NMR and biochemical studies. Cell Biol Int. 2005;29(11):890-897.
122. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. *Curr Opin Cell Biol*. 1998;10(1):123-130.

123. Bacus SS, Gudkov AV, Lowe M, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. *Oncogene*. 2001;20(2):147-155.

124. Van De Walle CG. Hydrogen as a cause of doping in zinc oxide. *Phys Rev Lett*. 2000;85(5):1012-1015.

125. Wang H, Xie C, Zhang W, Cai S, Yang Z, Gui Y. Comparison of dye degradation efficiency using ZnO powders with various size scales. *J Hazard Mater*. 2007;141(3):645-652.

126. Shafagh M, Rahmani F, Delirezh N. CuO nanoparticles induce cytotoxicity and apoptosis in human K562 cancer cell line via mitochondrial pathway, through reactive oxygen species and P53. *Iran J Basic Med Sci*. 2015;18(10):993-1000.